
|Videos|April 22, 2020
Regulatory Hurdles for Increased Availability of Cannabis-Infused Edibles
Author(s)Total Pharmacy Team
Advertisement
Merril Gilbert, founder and CEO of TraceTrust: One is getting it declassified as a Schedule I narcotic. It’s clearly not that. There is no addictive qualities: it’s a combination of other things. But it’s also, again, how do I counteract it and not knowing how it’s going to react for different people. You’re going to have the same reaction as if you have a peanut allergy and we have to be really conscious of that. So, again, creating a standard like we’re doing in this same manner and together with other types of certifications –nonGMO and vegan– and really aligning together, raising up together and not competing against each other is crucial now.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Overcoming the Structural Squeeze Through Policy and Coordination
2
Navigating Compounding Peptides and GLP-1s Through Regulations
3
Pharmacist Involvement Speeds Prior Authorization for GLP-1s
4
The 2026 GLP-1 Compounding Crackdown: A Pharmacist’s Guide
5


























